Combination therapy of continuous arterial infusion of nafamostat mesilate and arterial injection of human urinary trypsin inhibitor (ulinastatin) for severe acute pancreatitis

Ayumi Hara, Jun Arai, Hidehiko Matsukawa, Nagamu Inoue, Haruhiko Ogata, Yasushi Iwao, Masahiro Yoshioka, Toshifumi Hibi

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: We propose a treatment for severe acute pancreatitis that combines continuous arterial infusion (CAI) of nafamostat mesilate and arterial injection of the human urinary trypsin inhibitor, ulinastatin (UTI) to inhibit the activity of neutrophil elastase (PMN elastase) in the pancreas during the early stage of pancreatitis. The present study investigated effectiveness of this combination therapy in improving symptoms associated with pancreatitis. Methods: The diagnosis of severe acute pancreatitis followed the diagnostic criteria established by the Japanese Ministry of Health and Welfare in 1990. The present combination therapy was performed on a total of six patients with severe acute pancreatitis and shifts in the levels of different cytokines were measured. Results: The results showed that even a single injection of UTI administered during the placement of a continuous arterial infusion catheter was sufficient to eliminate pain. Shifts in the levels of different cytokines (PMN elastase, interleukin-6, and TNF α) were compared between patients with severe acute pancreatitis and the control group. No significant differences were observed in the pre-therapy levels of PMN elastase, interleukin-6 and TNFα between the two groups. However, after the start of therapy, the levels of these cytokines increased in some patients with severe pancreatitis. Conclusions: Our study suggests that the suppression of neutrophil activation in the pancreas by arterial injection of UTI during the early stage of pancreatitis is important in preventing its progression and the onset of multiple organ failure. And our study also suggests that the combination therapy must be applied to the treatment of severe pancreatitis.

Original languageEnglish
Pages (from-to)1265-1275
Number of pages11
JournalTherapeutic Research
Volume23
Issue number6
Publication statusPublished - 2002
Externally publishedYes

Fingerprint

Pancreatitis
Injections
Leukocyte Elastase
Therapeutics
Cytokines
Pancreas
Interleukin-6
urinastatin
nafamostat
Neutrophil Activation
Multiple Organ Failure
Catheters
Pain
Control Groups
Health

Keywords

  • Continuous arterial infusion
  • Cytokine
  • Human urinary trypsin inhibitor
  • Nafamostat mesilate
  • Severe acute pancreatitis
  • Ulinastatin

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Combination therapy of continuous arterial infusion of nafamostat mesilate and arterial injection of human urinary trypsin inhibitor (ulinastatin) for severe acute pancreatitis. / Hara, Ayumi; Arai, Jun; Matsukawa, Hidehiko; Inoue, Nagamu; Ogata, Haruhiko; Iwao, Yasushi; Yoshioka, Masahiro; Hibi, Toshifumi.

In: Therapeutic Research, Vol. 23, No. 6, 2002, p. 1265-1275.

Research output: Contribution to journalArticle

@article{891cbe9aa69e4953a98e43839aeee40d,
title = "Combination therapy of continuous arterial infusion of nafamostat mesilate and arterial injection of human urinary trypsin inhibitor (ulinastatin) for severe acute pancreatitis",
abstract = "Background: We propose a treatment for severe acute pancreatitis that combines continuous arterial infusion (CAI) of nafamostat mesilate and arterial injection of the human urinary trypsin inhibitor, ulinastatin (UTI) to inhibit the activity of neutrophil elastase (PMN elastase) in the pancreas during the early stage of pancreatitis. The present study investigated effectiveness of this combination therapy in improving symptoms associated with pancreatitis. Methods: The diagnosis of severe acute pancreatitis followed the diagnostic criteria established by the Japanese Ministry of Health and Welfare in 1990. The present combination therapy was performed on a total of six patients with severe acute pancreatitis and shifts in the levels of different cytokines were measured. Results: The results showed that even a single injection of UTI administered during the placement of a continuous arterial infusion catheter was sufficient to eliminate pain. Shifts in the levels of different cytokines (PMN elastase, interleukin-6, and TNF α) were compared between patients with severe acute pancreatitis and the control group. No significant differences were observed in the pre-therapy levels of PMN elastase, interleukin-6 and TNFα between the two groups. However, after the start of therapy, the levels of these cytokines increased in some patients with severe pancreatitis. Conclusions: Our study suggests that the suppression of neutrophil activation in the pancreas by arterial injection of UTI during the early stage of pancreatitis is important in preventing its progression and the onset of multiple organ failure. And our study also suggests that the combination therapy must be applied to the treatment of severe pancreatitis.",
keywords = "Continuous arterial infusion, Cytokine, Human urinary trypsin inhibitor, Nafamostat mesilate, Severe acute pancreatitis, Ulinastatin",
author = "Ayumi Hara and Jun Arai and Hidehiko Matsukawa and Nagamu Inoue and Haruhiko Ogata and Yasushi Iwao and Masahiro Yoshioka and Toshifumi Hibi",
year = "2002",
language = "English",
volume = "23",
pages = "1265--1275",
journal = "Therapeutic Research",
issn = "0289-8020",
publisher = "Life Science Publishing Co. Ltd",
number = "6",

}

TY - JOUR

T1 - Combination therapy of continuous arterial infusion of nafamostat mesilate and arterial injection of human urinary trypsin inhibitor (ulinastatin) for severe acute pancreatitis

AU - Hara, Ayumi

AU - Arai, Jun

AU - Matsukawa, Hidehiko

AU - Inoue, Nagamu

AU - Ogata, Haruhiko

AU - Iwao, Yasushi

AU - Yoshioka, Masahiro

AU - Hibi, Toshifumi

PY - 2002

Y1 - 2002

N2 - Background: We propose a treatment for severe acute pancreatitis that combines continuous arterial infusion (CAI) of nafamostat mesilate and arterial injection of the human urinary trypsin inhibitor, ulinastatin (UTI) to inhibit the activity of neutrophil elastase (PMN elastase) in the pancreas during the early stage of pancreatitis. The present study investigated effectiveness of this combination therapy in improving symptoms associated with pancreatitis. Methods: The diagnosis of severe acute pancreatitis followed the diagnostic criteria established by the Japanese Ministry of Health and Welfare in 1990. The present combination therapy was performed on a total of six patients with severe acute pancreatitis and shifts in the levels of different cytokines were measured. Results: The results showed that even a single injection of UTI administered during the placement of a continuous arterial infusion catheter was sufficient to eliminate pain. Shifts in the levels of different cytokines (PMN elastase, interleukin-6, and TNF α) were compared between patients with severe acute pancreatitis and the control group. No significant differences were observed in the pre-therapy levels of PMN elastase, interleukin-6 and TNFα between the two groups. However, after the start of therapy, the levels of these cytokines increased in some patients with severe pancreatitis. Conclusions: Our study suggests that the suppression of neutrophil activation in the pancreas by arterial injection of UTI during the early stage of pancreatitis is important in preventing its progression and the onset of multiple organ failure. And our study also suggests that the combination therapy must be applied to the treatment of severe pancreatitis.

AB - Background: We propose a treatment for severe acute pancreatitis that combines continuous arterial infusion (CAI) of nafamostat mesilate and arterial injection of the human urinary trypsin inhibitor, ulinastatin (UTI) to inhibit the activity of neutrophil elastase (PMN elastase) in the pancreas during the early stage of pancreatitis. The present study investigated effectiveness of this combination therapy in improving symptoms associated with pancreatitis. Methods: The diagnosis of severe acute pancreatitis followed the diagnostic criteria established by the Japanese Ministry of Health and Welfare in 1990. The present combination therapy was performed on a total of six patients with severe acute pancreatitis and shifts in the levels of different cytokines were measured. Results: The results showed that even a single injection of UTI administered during the placement of a continuous arterial infusion catheter was sufficient to eliminate pain. Shifts in the levels of different cytokines (PMN elastase, interleukin-6, and TNF α) were compared between patients with severe acute pancreatitis and the control group. No significant differences were observed in the pre-therapy levels of PMN elastase, interleukin-6 and TNFα between the two groups. However, after the start of therapy, the levels of these cytokines increased in some patients with severe pancreatitis. Conclusions: Our study suggests that the suppression of neutrophil activation in the pancreas by arterial injection of UTI during the early stage of pancreatitis is important in preventing its progression and the onset of multiple organ failure. And our study also suggests that the combination therapy must be applied to the treatment of severe pancreatitis.

KW - Continuous arterial infusion

KW - Cytokine

KW - Human urinary trypsin inhibitor

KW - Nafamostat mesilate

KW - Severe acute pancreatitis

KW - Ulinastatin

UR - http://www.scopus.com/inward/record.url?scp=0036033484&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036033484&partnerID=8YFLogxK

M3 - Article

VL - 23

SP - 1265

EP - 1275

JO - Therapeutic Research

JF - Therapeutic Research

SN - 0289-8020

IS - 6

ER -